Eli Lilly and Company announced the acquisition of Orna Therapeutics, a Boston-based biotechnology firm, for $2.4 billion in an all-cash transaction. The deal grants Lilly access to Orna's circular RNA technology platform and a portfolio of gene therapy candidates targeting autoimmune diseases, positioning the pharmaceutical giant to diversify its therapeutic offerings beyond its current blockbuster medications.
Orna's lead program, ORN-252, represents a significant asset for Lilly, utilizing proprietary in vivo chimeric antigen receptor T-cell technology that does not require cell extraction or manufacturing outside the patient's body. The candidate has completed preclinical development and is prepared to enter clinical trials, though market availability remains several years away. The acquisition reflects Lilly's strategic focus on replenishing its drug pipeline as it capitalizes on the commercial success of tirzepatide, its GLP-1 receptor agonist approved for diabetes and weight management.
The transaction underscores intensifying competition among major pharmaceutical companies to secure innovative gene therapy platforms. For Lilly, the deal addresses long-term pipeline sustainability while expanding its presence in the high-potential autoimmune disease segment, a therapeutic area with significant unmet medical needs and market opportunity.